Double hit lymphoma represents up to 14% of the patients with aggressive B-cell lymphoma and MYC/BCL2 DHL is most common, representing approximately 65% of all cases, followed by MYC/BCL2/BCL6 triple hit lymphoma, ~20%, and MYC/BCL6 DHL, ~15%. This evidence concerns the gene BCL6 and B-cell non-Hodgkin lymphoma.